Table 1. Baseline characteristics of the study subjects.
C19-A3 PIT
CharacteristicPlaceboLow frequencyHigh frequency
Number of subjects8109
Mean age (years; ±SD)28.9 ± 8.226.6 ± 5.530 ± 5.7
Gender (female:male)2:64:63:6
Body mass index (kg/m2; ±SD)23.1 ± 2.624.2 ± 5.525.6 ± 5.4
Number of autoantibodies (GAD65Ab, IA-2Ab, and ZnT8Ab):
  Single antibody–positive
12.5%50.0%11.1%
  Double antibody–positive25.0%30.0%11.1%
  Triple antibody–positive62.5%20.0%77.8%
Mean time from diagnosis to first dose (days; ±SD)95 ± 22.882.5 ± 16.091 ± 15.5
Mean glycated hemoglobin (mmol/mol; ±SD)62.5 + 13.758.4 + 14.951.7 + 6.83*
Average total daily insulin dose (IU Kg−1 day−1; ±SD)0.42 + 0.200.38 + 0.180.30 + 0.07
Stimulated C-peptide AUC (nM/min; ±SD)0.58 ± 0.250.81 ± 0.760.99 ± 0.73

*P = 0.02 versus placebo.